NCT04700787撤回1 期
A Phase 1, Multi-Center, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Sulopenem and Sulopenem Etzadroxil + Probenecid in Adolescent Patients With Bacterial Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Maximum plasma concentration
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous sulopenem and oral sulopenem etzadroxil/probenecid in adolescent patients.
详细描述
After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Hospitalized patients who are 12-18 years of age and who are receiving background antibiotic treatment for uncomplicated urinary tract infection, complicated urinary tract infection, acute pyelonephritis, or complicated intraabdominal infection, and who meet eligibility requirements will receive a single 1000 mg IV dose of sulopenem on Day 1. The following day, patients will receive a single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet. During treatment, pharmacokinetic samples will be collected and patients will be monitored for safety and tolerability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's parent/both parents or guardian must provide written informed consent and a statement of assent from the adolescent patient (if required by Institutional Review Board [IRB] according to local regulations and guidelines) must be obtained prior to any study-related procedures.
- •Patient is male or female adolescent who are ≥12 and <18 years of age.
- •Patient has a diagnosis of uUTI, cUTI, AP, or cIAI as documented by the treating physician
- •Patient will be hospitalized for urinary tract infection, acute pyelonephritis, or complicated intraabdominal infection for at least 48 hours and be receiving appropriate anti-infective treatment.
- •Patient must have sufficient venous access to permit administration of study drug, collection of PK samples, and monitoring of laboratory safety variables.
- •Female patients who are post-menarche must not be pregnant or breast feeding and must have a documented negative serum pregnancy test at Screening.
- •Post-menarchal females and post-pubertal males must agree to use a highly effective method of birth control with partners of childbearing potential throughout the duration of the study and for 1 month following the last dose of study drug.
- •Patient must be willing to follow all study procedures.
排除标准
- •Patient has creatinine clearance <90 mL/min using the Cockcroft-Gault formula.
- •Patient is unable to tolerate oral medications.
- •Patient has presence of Endocarditis, Meningitis, Necrotizing fasciitis, or Gas gangrene
- •Patient has signs of severe sepsis
- •Patient has evidence of active liver disease or hepatic dysfunction
- •Patient has neutropenia with absolute neutrophil count <500 cells/mm
- •Patient has history of solid organ transplantation reported at any time.
- •Patient has any finding that, in the view of the Investigator, would compromise the patient's safety requirements.
- •Patient has known allergies to penicillin, carbapenems, and/or cephalosporins, known allergy to probenecid, or severe allergic reactions to any drug in the past.
- •Patient has history of intolerance to β-lactam antibiotics, including but not limited to a history of clinically significant diarrhea/loose stools.
- •Patient has a history of hypersensitivity to the study drug or any of the excipients or to medicinal products with similar chemical structures.
- •Patient has involvement in the planning and/or conduct of this study
- •Patient has participated in any other clinical study where an investigational product was ingested within 30 days or 5 half-lives of the drug (whichever is longer) prior to the current study.
- •Patient has definite or suspected personal history or family history of clinically significant adverse drug reactions.
- •Patient has history or presence of GI, hepatic, or renal disease, or other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- •Patient had treatment in the previous 3 months with any drug known to have a well-defined potential for hepatotoxicity (eg, halothane).
- •Patient weighs <35 kg.
- •Patient is pregnant or lactating.
研究组 & 干预措施
Sulopenem
Experimental
Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
干预措施: Sulopenem (Drug)
结局指标
主要结局
Maximum plasma concentration
时间窗: To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose
Maximum plasma concentration (Cmax) of sulopenem at multiple timepoints after dose
次要结局
- Time to maximum plasma concentration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Time above minimum inhibitory concentration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Area under the plasma concentration-time curve from time zero to time of last quantifiable plasma concentration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Area under the plasma concentration-time curve from time zero extrapolated to infinity(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Percentage of area under the concentration-time curve extrapolated(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Terminal elimination half-life(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Total body clearance for intravenous administration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Apparent total body clearance for oral administration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Volume of distribution for intravenous administration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
- Apparent volume of distribution for oral administration(To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaAcute Myeloid LeukemiaNCT03333005Basilea Pharmaceutica20
终止
1 期
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of AgeInvasive Fungal InfectionsNCT05534529Mundipharma Research Limited32
已完成
1 期
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseAlzheimer DiseaseNCT04971733Eisai Inc.8
终止
4 期
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric SubjectsGastroesophageal Reflux DiseaseNCT02401035Pfizer19
已完成
1 期
Sildenafil IV Bolus StudyHypertension, PulmonaryNCT00800592Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12